Preprint
Article

This version is not peer-reviewed.

Current Serum 25-Hydroxyvitamin D and Hepatitis B Surface Antibody Seropositivity Among US Adults Reporting Hepatitis B Vaccination, 2017–2018

Submitted:

18 November 2026

Posted:

19 November 2026

You are already at the latest version

Abstract
Objectives: To evaluate whether current serum 25-hydroxyvitamin D [25(OH)D] is associated with current hepatitis B surface antibody (anti-HBs) seropositivity among US adults who report hepatitis B vaccination. The response to vaccination was not studied. Methods: This study included 1,382 US adults aged ≥18 years in the 2017–2018 National Health and Nutrition Examination Survey (NHANES) who reported ≥3 doses of hepatitis B vaccine and had measured 25(OH)D and anti-HBs. Survey-weighted logistic regression estimated odds ratios (OR) for anti-HBs positivity by 25(OH)D <50 versus ≥50 nmol/L, adjusted for demographics, income, body mass index, smoking, and season (n = 1,098). For comparison, all 2017–2018 adults regardless of vaccination status were also analyzed. Results: Among vaccinated adults, weighted anti-HBs positivity was 47.8% (95% CI 43.6–52.1), and 30.5% (unweighted) had 25(OH)D <50 nmol/L. Low 25(OH)D was not statistically significantly associated with anti-HBs positivity (adjusted OR 1.12, 95% CI 0.73–1.74), including among anti-HBc-negative adults (OR 1.15, 0.74–1.80). The OR was 1.07 (0.78–1.49) among all 2017–2018 adults. Conclusions: Among adults reporting complete vaccination, current 25(OH)D was not statistically significantly associated with anti-HBs positivity, and results were similar in all adults and in anti-HBc-negative adults. Because 25(OH)D was measured long after vaccination, these data cannot address vitamin D status at vaccination.
Keywords: 
;  ;  ;  ;  
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.